Controversies in the management of adjuvant breast cancer with taxanes: Review of the current literature

Arroyo, Patricia; Pérez, Ruth Ubago; Díez, Bárbara Cancela; Feijoo, M.A. Fernández; Magdalena, Jorge Hernández; Hernández, Miguel Ángel Calleja

doi:10.1016/j.ctrv.2010.06.002

Cited by 13 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The central role of taxanes in the therapy of common epithelial cancers is further highlighted by their ability to induce remissions in patients with anthracycline- or cis -platinum-resistant epithelial cancers [27,28]. DTX, in particular, is broadly indicated for the treatment of non-small cell lung cancer, and breast, prostate, stomach and head and neck cancers [29], though these results remain open to debate [30], and is clinically preferred to paclitaxel [29]. However, to our best of our knowledge, very few studies have tested the efficacy of small-sized nanoparticles to deliver DTX in metastatic BC models, and the development of a small (10–30 nm) nanocarrier for DTX is desperately needed.…”

Section: Introductionmentioning

confidence: 99%

Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model

Jin

Shao

et al. 2014

BMC Cancer

View full text Add to dashboard Cite

BackgroundThe small size of ultra-small nanoparticles makes them suitable for lymphatic delivery, and many recent studies have examined their role in anti-metastasis therapy. However, the anti-metastatic efficacy of small-sized nanocarriers loaded with taxanes such as docetaxel has not yet been investigated in malignant breast cancer.MethodsWe encapsulated docetaxel using poly(D,L-lactide)1300-b-(polyethylene glycol-methoxy)2000 (mPEG2000-b-PDLLA1300) to construct polymeric micelles with a mean diameter of 16.76 nm (SPM). Patient-like 4T1/4T1luc breast cancer models in Balb/c mice, with resected and unresected primary tumors, were used to compare the therapeutic efficacies of SPM and free docetaxel (Duopafei) against breast cancer metastasis using bioluminescent imaging, lung nodule examination, and histological examination.ResultSPM showed similar efficacy to Duopafei in terms of growth suppression of primary tumors, but greater chemotherapeutic efficacy against breast cancer metastasis. In addition, lung tissue inflammation was decreased in the SPM-treated group, while many tumor cells and neutrophils were found in the Duopafei-treated group.ConclusionSmall-sized mPEG2000-b-PDLLA1300 micelles could provide an enhanced method of docetaxel delivery in breast cancer metastasis, and may represent a valid chemotherapeutic strategy in breast cancer patients with resected primary tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model

Jin

Shao

et al. 2014

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…The central role of taxanes in the therapy of common epithelial cancers is further highlighted by their ability to induce remissions in patients with anthracycline- or cis -platinum-resistant epithelial cancers [ 18 ]. DTX, in particular, is broadly indicated for the treatment of non-small cell lung cancer, and breast, prostate, stomach and head and neck cancers [ 19 ], though these results remain open to debate [ 20 ], and is clinically preferred to paclitaxel [ 19 ]. However, to our best of our knowledge, very few studies have tested the efficacy of small-sized nanoparticles to deliver DTX in PDAC, and developing a small (10–30 nm) nanocarrier for DTX is desperately needed.…”

Section: Introductionmentioning

confidence: 99%

Docetaxel-Encapsulating Small-Sized Polymeric Micelles with Higher Permeability and Its Efficacy on the Orthotopic Transplantation Model of Pancreatic Ductal Adenocarcinoma

Jin

et al. 2014

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) elicits a dense stromal response that blocks vascular access because of pericyte coverage of vascular fenestrations. In this way, the PDAC stroma contributes to chemotherapy resistance, and the small-sized nanocarrier loaded with platinum has been adopted to address this problem which is not suitable for loading docetaxel (DTX). In the present study, we used the poly(d,l-lactide)-b-polyethylene glycol-methoxy (mPEG-b-PDLLA) to encapsulate DTX and got a small-sized polymeric micelle (SPM); meanwhile we functionalized the SPM’s surface with TAT peptide (TAT-PM) for a higher permeability. The diameters of both SPM and TAT-PM were in the range of 15–26 nm. In vitro experiments demonstrated that TAT-PM inhibited Capan-2 Luc PDAC cells growth more efficiently and induced more apoptosis compared to SPM and Duopafei. The in vivo therapeutic efficiencies of SPM and TAT-PM compared to free DTX was investigated on the orthotopic transplantation model of Capan-2 Luc. SPM exerted better therapeutic efficiency than free DTX, however, TAT-PM didn’t outperformed SPM. Overall, these results disclosed that SPM could represent a new therapeutic approach against pancreatic cancer, but its permeability to PDAC was not the only decisive factor.

show abstract

“…9–11 Paclitaxel is clinically used in the treatment of breast cancer, advanced ovarian cancer, non-small cell lung cancer, and advanced forms of Kaposi's sarcoma, 12 whereas docetaxel is employed against breast cancer, non-small cell lung cancer, gastric cancer, prostate cancer, and squamous cell carcinoma of the head and neck. 13–15 Cabazitaxel (Jevtana, II ′), a recently introduced derivative of docetaxel (docetaxel methylated at C7 and C10 hydroxyl groups), is used to treat hormone-refractory prostate cancer. The latter success underscores the importance of fine-tuning the structures of these agents in order to amplify their selectivity towards specific cancers, a theme that is currently attracting special attention in view of personalized medicine.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents

Nicolaou

Valiulin

2013

Org. Biomol. Chem.

View full text Add to dashboard Cite

Reaction of 10-deacetylbaccatin III (III) and its 7-TES derivative (IV) with DAST under various conditions resulted in the formation of an array of new fluorinated and non-fluorinated 13-keto taxoid compounds (2a–4a) through a vinylogous pinacol-pinacolone rearrangement. Further fluorination of some of these products (2a, 3a) with NFSi or Selectfluor gave additional derivatives. Sodium borohydride reduction of the 13-keto group of these products (2a, 2b, 3a, 3b, 4a, 8, 9, 11–14) led to a series of 9α-hydroxy taxoid derivatives, which were esterified using the docetaxel side chain employing the corresponding protected β-lactam, followed by deprotection to furnish a library of docetaxol analogs and related compounds. A selected number of synthesized compounds (7, 10, 19a, 19b, 21a, 21b, 23, 27, 29, 34–36) were submitted to the National Cancer Institute (NCI) 60 cell line screening program and tested for cytotoxic properties. Taxoids 19a, 19b, 21a, 21b, 23, 27, 29, 34 and 35 were found to exhibit significant anticancer activity against various cancerous cell lines with 23, 27, and 29 being the most potent compounds, demonstrating GI50 values of ≤ 5 nM in several assays.

show abstract

Controversies in the management of adjuvant breast cancer with taxanes: Review of the current literature

Cited by 13 publications

References 22 publications

Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model

Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model

Docetaxel-Encapsulating Small-Sized Polymeric Micelles with Higher Permeability and Its Efficacy on the Orthotopic Transplantation Model of Pancreatic Ductal Adenocarcinoma

Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents

Contact Info

Product

Resources

About